What is the 4-Piperidinecarboxylic acid,1-[3-chloro-5-[[[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]amino]carbonyl]-2-pyridinyl]-, (2Z)-2-butenedioate (1:1)?

4-Piperidinecarboxylic acid,1-[3-chloro-5-[[[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]amino]carbonyl]-2-pyridinyl]-, (2Z)-2-butenedioate (1:1) is , while it's Molecular Formula is C29H34Cl2N6O3S2.C4H4O4.

What is the CAS number for 4-Piperidinecarboxylic acid,1-[3-chloro-5-[[[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]amino]carbonyl]-2-pyridinyl]-, (2Z)-2-butenedioate (1:1)?

The CAS number of 4-Piperidinecarboxylic acid,1-[3-chloro-5-[[[4-(4-chloro-2-thienyl)-5-(4-cyclohexyl-1-piperazinyl)-2-thiazolyl]amino]carbonyl]-2-pyridinyl]-, (2Z)-2-butenedioate (1:1) is 677007-74-8.

Product Class

677007-74-8

Product Name：Avatrombopag maleate
Molecular Formula：C29H34Cl2N6O3S2.C4H4O4
Purity：99%
Molecular Weight：

Inquiry

Product Details:

CasNo： 677007-74-8

Molecular Formula： C29H34Cl2N6O3S2.C4H4O4

Factory Supply Avatrombopag maleate,Wholesale 677007-74-8 Cheap Price

Molecular Formula:C29H34Cl2N6O3S2.C4H4O4
Molecular Weight:

Avatrombopag maleate(Cas 677007-74-8) Usage

Description

Avatrombopag maleate is the maleate salt form of avatrombopag, which is an orally available platelet thrombopoietin receptor (TPOR; MPL) agonist. It works by stimulating megakaryopoiesis, the process by which platelets are produced from megakaryocytes in the bone marrow.

Uses

Avatrombopag maleate, marketed as Doptelet by Dova Pharmaceuticals, is indicated for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo medical or dental procedures. Thrombocytopenia refers to a low number of platelets, which are essential for blood clotting. By increasing platelet production, avatrombopag helps prevent bleeding complications during procedures.

677007-74-8 Relevant articles

Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease

H Al-Samkari

, Drugs of today: Medicamentos de actualidad, 2018

This review will evaluate the preclinical pharmacology, pharmacokinetics, clinical studies, safety, indications and drug interactions of avatrombopag, with a focus on its use for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease.

POLYMORPHIC FORMS OF AVATROMBOPAG MALEATE

RR Jetti，NM Pilli，BR Padala，Y Sangvikar，S Jayachandra，D Bhatraju

WO2020044364A1

The present invention relates generally to pharmaceutically active compounds and more specifically to crystalline Form M1 of Avatrombopag, crystalline Form M2 of Avatrombopag, crystalline Form M3 of Avatrombopag, crystalline Form M4 of Avatrombopag, crystalline Form M5 of Avatrombopag, crystalline Form M1 of Avatrombopag maleate, crystalline Form M2 of Avatrombopag maleate, crystalline Form M3 of Avatrombopag maleate, amorphous Avatrombopag, amorphous Avatrombopag maleate, amorphous solid dispersions of Avatrombopag maleate and processes for the preparation thereof.

Relevant Products

Pazopanib Hcl
CAS：635702-64-6
Bictegravir Sodium
CAS：1807988-02-8
Tegoprazan
CAS：942195-55-3